Essential Psychopharmacology, 2017: From Neuroscience to Advances in Treatment

Carl Salzman, MD, Alan I. Green, MD, Russell G. Vasile, MD, Roscoe G. Brady, Jr. MD, PhD, & Barbara Coffey, MD

July 31 – August 4, 2017 • Monday – Friday

See Accreditation

REGISTER NOW

 This seminar will provide an updated review of recent advances in neurobiology with a focus on the pathophysiology of the major psychiatric disorders. Specific categories of treatment will include treatment of schizophrenia, bipolar disorder, depression, and anxiety spectrum disorders. The effectiveness of atypical and conventional antipsychotic drugs as wellas newer medications will be reviewed. The seminar will address strategies for bipolar patients who are noncompliant or treatment-resistant, approaches to the acutely psychotic, recovering psychotic patient, and the concept of early intervention. The role of switch versus augmentation, and combination strategies for treatment-resistant depression will be reviewed as well as best treatments for subtypes of major depression including atypical depression. The role of psychopharmacology in the treatment of generalized anxiety disorders, obsessive-compulsive symptoms, panic symptoms, and traumatic syndromes will be highlighted. The latest advances in child and adolescent psychopharmacology will be presented. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards/benefits of polypharmacy drug interactions.

 

Upon completion of this seminar, participants will be able to:

 

  • Evaluate psychotropic drug treatment options with particular emphasis on recent advances and practical prescribing information;
  • Apply the latest research in neurobiology and genetics to clinical decision making;
  • Incorporate evidence-based approaches to treating acutely psychotic and recovering psychotic patients;
  • Implement clinical practice with mood stabilizers based on the best randomized clinical trials for bipolar disorder and depression; •
  • Implement clinical practice with antidepressants based on the best randomized clinical trials for depression and bipolar disorder; •
  • Implement treatment strategies for depressive and bipolar patients, including bipolar patients who are noncompliant or treatment resistant; •
  • Determine the role of antidepressants in the life cycle of women;
  • Determine when to implement medical switch versus augmentation strategies for treatment resistant depression;
  • Analyze the role of psychopharmacology in the treatment of generalized anxiety disorder, obsessive symptoms, panic symptoms, and traumatic syndromes;
  • Identify mechanisms of sleep disorders and their effective psychopharmacologic treatment;
  • Consider the interplay between pharmacologic and non-pharmacologic treatments;
  • Learn the latest advances in child and adolescent psychopharmacology;
  • Utilize recent advances in treatment of psychiatric disturbances into practical prescribing information.

 

SCHEDULE

 

Monday, July 31, 2017

Carl Salzman, MD

  • Basic review of neurotransmitter and synaptic function; factors of gene expression; second and third messenger systems; neurohormones.
  • The “Basic Review” (continued).

 

Tuesday, August 1, 2017

Alan Green, MD

  • Biology and treatment of psychotic disorders: the new generation of antipsychotic drugs; clinical aspects of treatment: use of typical and atypical neuroleptics (including clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and experimental agents); Q&A.
  • Concepts of early intervention and prevention; optimizing outcomes; treatment of alcohol and substance abuse in patients with psychosis.

 

Wednesday, August 2, 2017

Russell Vasie, MD

  • Overview of Depressive Disorders with a focus on psychopharmacologic management of major depression, including bipolar depression and other depressive subtypes such as psychotic depression, atypical depression and melancholia; approaches to treatment resistant depression; review of emerging treatments for depression including vagal nerve stimulation and transcranial magnetic stimulation; Q&A.
  • Overview of Anxiety Disorders with a focus on psychopharmacological management of anxiety disorders: panic disorder, generalized anxiety disorder, obsessive compulsive disorder, phobic disorders and posttraumatic stress disorder; use of SSRIs, SNRIs, and novel neuroleptics as well as benzodiazepines; management of difficult-to-treat anxiety disorders; recent innovations in anxiety management.

 

Thursday, August 3, 2017

Roscoe Brady, MD, PhD

  • Pharmacologic treatment of bipolar disorder: use of mood stabilizers and anticonvulsants. Q&A.
  • Treatment algorithms and recommendations for dosing and management of adverse effects; review of pharmacokinetic and metabolic differences between adults and children.

 

Friday, August 4, 2017

Barbara Coffey, MD

  • Diagnosis and pharmacological treatment of psychiatric disorders in children and adolescents, including ADHD, affective and anxiety disorders, tic disorders, and psychotic disorders; Q&A.
  • Treatment algorithms and recommendations for dosing and management of adverse effects; review of pharmacokinetic and metabolic differences between adults and children.